# My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

> **NCT02091141** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 673 (actual)

## Conditions studied

- Neoplasms
- Solid Tumors
- Biliary Cancer
- Salivary Cancer
- Bladder Cancer

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Erlotinib
- **DRUG:** Vemurafenib
- **DRUG:** Cobimetinib
- **DRUG:** Vismodegib
- **DRUG:** Alectinib
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT02091141
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-14
- **Primary completion:** 2023-05-24
- **Final completion:** 2023-05-24
- **Target enrollment:** 673 (ACTUAL)
- **Last updated:** 2024-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02091141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02091141, "My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02091141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*